188
Participants
Start Date
September 12, 2017
Primary Completion Date
November 12, 2018
Study Completion Date
February 22, 2019
ZGN-1061
ZGN-1061 is a methionine aminopeptidase 2 inhibitor
Placebo
Placebo has the same excipients and appearance as ZGN-1061
Optimal Clinical Trials, Auckland
The Boden Institute, Sydney
Holdsworth House Medical Practice, Sydney
Middlemore Hospital, Auckland
Pendlebury Research, Sydney
The Aim Centre, Merewether
Coffs Harbour GP SuperClinic, Coffs Harbour
Northside Health, Coffs Harbour
Lakeland Clinical Trials, Rotorua
Royal Melbourne Hospital, Parkville
P3 Research Tauranga, Tauranga
Eastern Clinical Research Unit (ECRU), Box Hill
Clinical Trials New Zealand Ltd, Hamilton
Barwon Health, Geelong
Q-Pharm, Herston
P3 Research Hawkes Bay, Hastings
Griffith University, Gold Coast Campus, Southport
Southern Adelaide Diabetes & Endocrine Services, Daw Park
P3 Research Wellington, Newtown
Wellington Hospital, Wellington
Christchurch Diabetes Centre, Christchurch
Southern Clinical Trials, Christchurch
Lipid and Diabetes Research Group, Christchurch
Zafgen, Inc.
INDUSTRY